Cediranib: Difference between revisions
Content deleted Content added
categorizing |
LinkinPark (talk | contribs) |
||
| Line 1: | Line 1: | ||
#REDIRECT [[Cediranib]] |
|||
{{drugbox | |
|||
| IUPAC_name = 4-[(4-fluoro-2-methyl-1''H''-indol-5-yl)oxy]-6-methoxy-<br>7-[3-(pyrrolidin-1-yl)propoxy]quinazoline |
|||
| image = AZD2171.svg |
|||
| width = 250px |
|||
| CAS_number = |
|||
| ATC_prefix = |
|||
| ATC_suffix = |
|||
| PubChem = |
|||
| DrugBank = |
|||
| C = 25 | H = 27 | F = 1 | N = 4 | O = 3 |
|||
| molecular_weight = 450.5 g/mol |
|||
| bioavailability = |
|||
| protein_bound = |
|||
| metabolism = |
|||
| elimination_half-life = 12 to 35 hours |
|||
| excretion = |
|||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|||
| pregnancy_US = <!-- A / B / C / D / X --> |
|||
| pregnancy_category = |
|||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S8 --> |
|||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|||
| legal_status = |
|||
| routes_of_administration = Oral |
|||
}} |
|||
'''AZD2171''' (tentative trade name '''Recentin''') is a potent [[kinase inhibitor|inhibitor]] of [[vascular endothelial growth factor]] (VEGF) receptor [[tyrosine kinase]]s. It is being developed by [[AstraZeneca]] as a possible chemotherapeutic agent for oral administration. |
|||
[[As of 2007]], it is undergoing [[Clinical trial#Phase I|Phase I]] [[clinical trial]]s for the treatment of [[Lung cancer#Non-small cell lung cancer|non-small cell]] [[lung cancer]] and [[colorectal cancer]] in adults, as well as tumors of the [[central nervous system]] in children. |
|||
==Further reading== |
|||
*{{cite journal |author=Wedge S, Kendrew J, Hennequin L ''et al''. |title=AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer |journal=Cancer Res |volume=65 |issue=10 |pages=4389–400 |year=2005 |pmid=15899831}} |
|||
==External links== |
|||
*[http://www.cancerline.com/cancerlinehcp/15602_15632_9_3_1.aspx AZD2171—AstraZeneca Pipeline] |
|||
{{Chemotherapeutic agents}} |
|||
{{pharma-stub}} |
|||
[[Category:Tyrosine kinase inhibitors]] |
|||
Revision as of 11:54, 21 December 2007
Redirect to: